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Amyotrophic lateral sclerosis (ALS) is a progressive, paralytic disorder characterized by degeneration of motor neurons in the brain and spinal cord. It begins insidiously with focal weakness but spreads relent-
lessly to involve most muscles, including the diaphragm. Typically, death due to 
respiratory paralysis occurs in 3 to 5 years.
Motor neurons are grouped into upper populations in the motor cortex and 
lower populations in the brain stem and spinal cord; lower motor neurons inner-
vate muscle (Fig. 1). When corticospinal (upper) motor neurons fail, muscle stiff-
ness and spasticity result. When lower motor neurons become affected, they ini-
tially show excessive electrical irritability, leading to spontaneous muscle twitching 
(fasciculations); as they degenerate, they lose synaptic connectivity with their target 
muscles, which then atrophy.
ALS typically begins in the limbs, but about one third of cases are bulbar, heralded 
by difficulty chewing, speaking, or swallowing. Until late in the disease, ALS 
spares neurons that innervate the eye and sphincter muscles. The diagnosis is 
based primarily on clinical examination in conjunction with electromyography, to 
confirm the extent of denervation, and laboratory testing, to rule out reversible 
disorders that may resemble ALS.1,2
A representative case involves a 55-year-old patient who was evaluated for foot 
drop, which had begun subtly 4 months earlier with the onset of muscle cramping 
in the right calf as a result of volitional movement (known as volitional cramping) 
and had progressed to severe weakness of ankle dorsiflexion and knee extension. 
In addition to these features, the physical examination revealed atrophy of the 
right calf and hyperreflexia of the right biceps and of deep tendon reflexes at both 
knees and both ankles. The neurologic examination was otherwise normal. Elec-
tromyography showed evidence of acute muscle denervation (fibrillations) in all 
four limbs and muscle reinnervation in the right calf (high-amplitude compound 
muscle action potentials). Imaging of the head and neck revealed no structural 
lesions impinging on motor tracts, and the results of laboratory studies were nor-
mal, findings that ruled out several disorders in the differential diagnosis, such as 
peripheral neuropathy, Lyme disease, vitamin B12 deficiency, thyroid disease, and 
metal toxicity.3 A full evaluation disclosed no evidence of a reversible motor neuron 
disorder, such as multifocal motor neuropathy with conduction block, which is 
typically associated with autoantibodies (e.g., anti-GM1 ganglioside antibodies) 
and can be effectively treated with intravenous immune globulin.4
The clinical presentation of ALS is heterogeneous with respect to the popula-
tions of involved motor neurons and survival (Fig. 2).2 When there is prominent 
involvement of frontopontine motor neurons that serve bulbar functions, a strik-
ing finding is emotional lability, indicating pseudobulbar palsy, which is charac-
terized by facial spasticity and a tendency to laugh or cry excessively in response 
to minor emotional stimuli.
Dan L. Longo, M.D., Editor
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In primary lateral sclerosis, there is selective 
involvement of corticospinal and corticopontine 
motor neurons, with few findings of lower motor 
neuron dysfunction.5 Primary lateral sclerosis is 
ruled out in the representative case described 
above because of the atrophy and electromyo-
graphic findings, which are indicative of lower 
motor neuron disease. Primary lateral sclerosis 
progresses slowly, with severe spastic muscle 
stiffness and little muscle atrophy. This disorder 
overlaps clinically with a broad category of corti-
cospinal disorders designated as hereditary spas-
tic paraplegias, which are typically symmetrical 
in onset, slowly progressive, and sometimes asso-
ciated with sensory loss and other multisystem 
findings. In primary lateral sclerosis but not 
hereditary spastic paraplegias, bulbar involve-
ment may be prominent. In progressive muscu-
lar atrophy, lower motor neuron involvement is 
predominant, with little spasticity. The hyperre-
flexia in the representative case is inconsistent 
with progressive muscular atrophy.
During the past two decades, it has been recog-
nized that 15 to 20% of persons with ALS have 
progressive cognitive abnormalities marked by 
behavioral changes, leading ultimately to de-
mentia.6 Since these behavioral alterations corre-
late with autopsy evidence of degeneration of the 
frontal and temporal lobes, the condition is des-
ignated frontotemporal dementia. It was formerly 
called Pick’s disease.
 Epidemiol o gic Fe at ur es
In Europe and the United States, there are 1 or 
2 new cases of ALS per year per 100,000 people; 
the total number of cases is approximately 3 to 
5 per 100,000.7,8 These statistics are globally fairly 
uniform, although there are rare foci in which 
ALS is more common. The incidence and preva-
lence of ALS increase with age. In the United 
States and Europe, the cumulative lifetime risk 
of ALS is about 1 in 400; in the United States 
alone, 800,000 persons who are now alive are 
expected to die from ALS.9 About 10% of ALS 
cases are familial, usually inherited as dominant 
traits.10 The remaining 90% of cases of ALS are 
sporadic (occurring without a family history). In 
cases of sporadic ALS, the ratio of affected 
males to affected females may approach 2:1; in 
familial ALS, the ratio is closer to 1:1. ALS is the 
most frequent neurodegenerative disorder of 
midlife, with an onset in the middle-to-late 50s. 
An onset in the late teenage or early adult years 
is usually indicative of familial ALS. The time 
Figure 1. The Motor System.
The motor system is composed of corticospinal (upper) motor neurons 
in the motor cortex and bulbar and spinal (lower) motor neurons, which 
innervate skeletal muscle.
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from the first symptom of ALS to diagnosis is 
approximately 12 months, a problematic delay if 
successful therapy requires early intervention. 
Because an abundance of ALS genes have now 
been identified, it will probably be informative 
to reanalyze this epidemiologic profile of ALS 
with stratification according to genetically de-
fined subtypes.
Pathol o gic a l Ch a r ac ter is tics
The core pathological finding in ALS is motor 
neuron death in the motor cortex and spinal 
cord; in ALS with frontotemporal dementia, 
neuronal degeneration is more widespread, oc-
curring throughout the frontal and temporal 
lobes. Degeneration of the corticospinal axons 
causes thinning and scarring (sclerosis) of the 
lateral aspects of the spinal cord. In addition, as 
the brain stem and spinal motor neurons die, 
there is thinning of the ventral roots and dener-
vational atrophy (amyotrophy) of the muscles of 
the tongue, oropharynx, and limbs. Until late in 
the disease, ALS does not affect neurons that 
innervate eye muscles or the bladder. Degenera-
tion of motor neurons is accompanied by neuro-
inflammatory processes, with proliferation of 
astroglia, microglia, and oligodendroglial cells.11,12 
A common feature in cases of both familial and 
sporadic ALS is aggregation of cytoplasmic pro-
teins, prominently but not exclusively in motor 
neurons. Some of these proteins are common in 
most types of ALS. This is exemplified by the 
nuclear TAR DNA-binding protein 43 (TDP-43), 
which in many cases of ALS is cleaved, hyper-
phosphorylated, and mislocalized to the cyto-
plasm.13 Aggregates of ubiquilin 2 are also 
common,14 as are intracytoplasmic deposits of 
wild-type superoxide dismutase 1 (SOD1) in spo-
radic ALS.15 Many protein deposits show evi-
dence of ubiquitination; threads of ubiquitinated 
TDP-43 are prominent in motor neurons, both 
terminally and before atrophy of the cell body. 
Given the diverse causes of ALS, it is not surpris-
ing that some types of aggregates are detected 
only in specific ALS subtypes (e.g., dipeptide 
aggregates and intranuclear RNA deposits in 
C9ORF72 ALS).
Gene tic Fe at ur es
Evolving technologies for gene mapping and 
DNA analysis have facilitated the identification 
of multiple ALS genes (Fig. 3). SOD1 was the first 
ALS gene to be identified, in 1993.16 More than 
120 genetic variants have been associated with a 
risk of ALS17 (http://alsod . iop . kcl . ac . uk). Several 
criteria assist in identifying those that are most 
meaningful. The strongest confirmation is vali-
dation in multiple independent families and co-
horts. Also supportive are an increased burden 
of the variant in cases relative to controls and 
the predicted consequences of the variant (e.g., 
missense mutation vs. truncation). It has proved 
almost impossible to predict a variant’s rele-
vance to ALS from the biologic features of the 
gene itself. As shown in Figure 3, at least 25 
Figure 2. Phenotype and Survival in Amyotrophic Lateral Sclerosis (ALS).
Panel A shows survival curves for two types of ALS (spinal­onset and bulbar­
onset) and two other motor neuron diseases (primary lateral sclerosis and 
progressive muscular atrophy). Panel B shows lateral atrophy and furrow­
ing of the tongue in a patient with ALS, findings that reflect denervation 
due to degeneration of bulbar motor neurons. Panel C shows thinned arms 
and shoulders, findings that are typical of the flail­arm syndrome, which 
occurs in patients with ALS and is associated with protracted survival.
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genes have now been reproducibly implicated in 
familial ALS, sporadic ALS, or both.18-20
A by-product of the genetic studies that is 
highly relevant to therapeutic development has 
been the generation of mouse models of ALS. 
Strikingly, transgenic expression of mutant SOD1 
protein21 and, more recently, profilin 1 (PFN1)22 
generates a neurodegenerative, paralytic process 
in mice that mimics many aspects of human 
ALS. An important lesson from transgenic mod-
els of TDP-43 and FUS (fused in sarcoma) is that 
levels of the normal protein are tightly con-
trolled. In contrast with SOD1, forced expression 
of high levels of normal TDP-43 by itself triggers 
motor neuron degeneration.23 Mouse models of 
C9orf72 (the 72nd open reading frame identified 
on chromosome 9, the most commonly mutated 
gene in ALS) have now also been generated for 
C9ORF72 ALS and are discussed below.
Correlations between genetic variants and 
different clinical profiles in ALS, such as age at 
onset, disease duration, and site of onset, have 
been defined (Table 1). An important example is 
the gene that encodes the enzyme ephrin A4 
(EPHA4)33 — lower levels of expression of EPHA4 
correlate with longer survival. Some genetic vari-
ants influence both susceptibility and phenotype. 
For example, progression is accelerated in pa-
tients with the common A4V mutation30 of SOD1 
and in patients with the P525L mutation of FUS/
TLS; the latter may lead to fulminant, childhood-
onset motor neuron disease.28
Concep t s in Patho genesis
A comprehensive explanation for ALS must in-
clude both its familial and sporadic forms, as well 
as categories of phenotypic divergence that arise 
even with the same proximal trigger, such as a 
gene mutation. A general presumption has been 
that the disease reflects an adverse interplay 
between genetic and environmental factors. An 
alternative view postulates that all cases of ALS 
are a consequence primarily of complex genetic 
factors. Several perspectives suggest that the 
pathogenesis of ALS entails a multistep process.34
Lessons from Familial ALS
There is striking heterogeneity in the genetic 
causes of familial ALS, but familial ALS and 
sporadic ALS have similarities in their patho-
logical features, as well as in their clinical fea-
tures, suggesting a convergence of the cellular 
and molecular events that lead to motor neuron 
degeneration. These points of convergence de-
fine targets for therapy.
A working view of the present panel of ALS 
genes is that they cluster in three categories,19 
involving protein homeostasis, RNA homeosta-
sis and trafficking, and cytoskeletal dynamics 
(Fig. 4). These mechanisms are not exclusive. For 
example, protein aggregates may sequester pro-
teins that are important in RNA binding, thereby 
perturbing RNA trafficking and homeostasis. 
Moreover, these mechanisms are detected in the 
context of both familial ALS and sporadic ALS; 
some nonmutant proteins also have a propensity 
to misfold and aggregate in ALS, much like their 
mutant counterparts (e.g., SOD1 and TDP-43).
Downstream of each category are diverse 
forms of cellular abnormalities, including the 
deposition of intranuclear and cytosolic protein 
and RNA aggregates, disturbances of protein 
degradative mechanisms, mitochondrial dysfunc-
tion, endoplasmic reticulum stress, defective 
nucleocytoplasmic trafficking, altered neuro-
nal excitability, and altered axonal transport. 
In most cases, these events activate and recruit 
nonneuronal cells (astrocytes, microglia, and 
oligodendroglia), which exert both salutary and 
Figure 3. ALS Gene Discovery since 1990.
The cumulative numbers of known ALS genes have increased rapidly. The 
size of each circle reflects the proportion of all familial ALS cases associat­
ed with that gene (e.g., 20% for SOD1 and 45% for C9ORF72). Blue circles 
indicate genes associated only with familial ALS, red circles indicate genes 
associated only with sporadic ALS, and circles that are half blue and half 
red indicate genes associated with both familial and sporadic ALS. Each of 
these genes has been found to be mutated in more than one ALS­affected 
family or in multiple, unrelated cases of sporadic ALS.
G
en
e 
C
ou
nt
30
20
25
15
10
5
1995 2000 2005 2010 2015 2020
Year of Discovery
0
1990
SOD1
ANG
VAPB
SQSTM1
DCTN1
FUS
UNC13A
ATXN2
C9ORF72
HNRNPA1
CHCHD10
SCFD1
MOBP
C21ORF2
NEK1
VCP
TARDBP
DAO
TAF15
OPTN
UBQLN2 PFN1
MATR3
TBK1
TUBA4A
Implicated in protein homeostasis
Involved in altered RNA-binding proteins
Involved in cytoskeletal proteins
The New England Journal of Medicine 
Downloaded from nejm.org at KINGS COLLEGE LONDON on July 20, 2017. For personal use only. No other uses without permission. 
 Copyright © 2017 Massachusetts Medical Society. All rights reserved. 
n engl j med 377;2 nejm.org July 13, 2017166
T h e  n e w  e ngl a nd  j o u r na l  o f  m e dic i n e
negative influences on motor neuron viability. 
The diverse downstream abnormalities may 
differentially affect subcellular compartments 
(dendrites, soma, axons, and neuromuscular 
junctions). One implication of this model is that 
successful therapy for ALS will require simulta-
neous interventions in multiple downstream 
pathways.
Genes That Influence Protein Homoeostasis
The most extensively investigated pathological 
finding in ALS has been the accumulation of 
aggregated proteins and corresponding defects 
in the cellular pathways for protein degradation. 
Mutant SOD1 frequently forms intracellular ag-
gregates. Genes that encode adapter proteins in-
volved in protein maintenance and degradation 
are also implicated in ALS. These include valo-
sin-containing protein (VCP)35 and the proteins 
optineurin (OPTN),36 TANK-binding kinase 1 
(TBK1),37-39 and sequestosome 1 (SQSTM1/p62)40 
(Fig. 4A). The TBK1–OPTN axis is interwoven in 
other neurodegenerative disorders; for example, 
the Parkinson’s disease gene PINK1 encodes a 
protein that acts upstream of TBK1 in the mobi-
lization of mitophagy.
Genes That Influence RNA Homeostasis  
and Trafficking
The most rapidly expanding category of ALS 
genes encodes proteins that interact with RNA. 
The first protein to be discovered was TDP-43,13 
whose mislocalization from the nucleus to the 
cytosol, cleavage, phosphorylation, and ubiquiti-
nation were initially illuminated in sporadic ALS 
and frontotemporal dementia. However, it be-
came apparent that mutations in TARDBP, the 
gene encoding TDP-43, can cause familial ALS.41 
Mislocalization and post-translational modifica-
tion of TDP-43 are observed in many neurode-
Gene
Minor Allele Frequency or 
Expression Level Phenotype Study
Site of Onset
Effect of Minor Allele 
on Age at Onset*
Effect of Minor 
Allele on Survival†
Genomewide association 
study
rs3011225­1p34 0.22 2 yr later Ahmeti et al.24
UNC13A 0.40 Shorter by 5–10 mo Diekstra et al.25
CAMTA1 0.26 Shorter by about 5 
mo
Fogh et al.26
IDE 0.03 Shorter by about 7 
mo
Fogh et al.26
Known ALS genes
C9ORF72 Up to 0.08 Primarily bulbar Cooper­Knock et al.27
FUS-P525L Rare variation Many years earlier Shorter by several 
months
Conte et al.28
PFN1 Rare variation Limb Wu et al.29
SOD1-A4V Rare variation Limb Shorter by several 
months
Cudkowicz et al.30
SOD1/SOD1 Rare variation Many years earlier Shorter by several 
months
Winter et al.31
Modifier genes
APOE Expression increased Longer by several 
months
Lacomblez et al.32
EPHA4 Expression decreased Longer by several 
months
Van Hoecke et al.33
*  The effect of the minor allele on age is shown relative to a cohort with the major allele.
†  The effect of the minor allele on survival is shown relative to a cohort with the major allele.
Table 1. Genetic Variants That Influence the Phenotype in Amyotrophic Lateral Sclerosis.
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generative diseases. FUS-TLS encodes another 
RNA-binding protein, homologous to TDP-43, 
which in mutant form also causes ALS.42,43 Why 
mutated genes encoding RNA-binding proteins 
cause ALS is not clear. These proteins have 
multiple functions in gene splicing, surveil-
lance of transcripts after splicing, generation of 
microRNA, and axonal biologic processes. Most 
of these proteins have low-complexity domains 
that permit promiscuous binding not only to 
RNA but also to other proteins. The ALS-related 
mutations heighten this binding propensity, 
leading to self-assembly of the proteins and the 
formation of aggregates.44 This auto-aggregation 
is facilitated in stress granules, which are non–
membrane-bound structures formed under cell 
stress that contain RNA complexes stalled in 
translation.45-47 The self-assembly of mutant RNA-
binding proteins may induce toxic, self-propagat-
ing conformations that disseminate disease with-
in and between cells in a manner analogous to 
that of prion proteins.
The most commonly mutated gene in ALS is 
C9ORF72.48-50 The C9ORF72 protein has a role in 
nuclear and endosomal membrane trafficking 
and autophagy. A noncoding stretch of six nucle-
otides is repeated up to approximately 30 times 
in normal persons. Expansions of this segment 
to hundreds or thousands of repeats cause famil-
ial ALS and frontotemporal dementia; in addition, 
these expansions sometimes cause sporadic ALS. 
Several mechanisms may contribute to the neuro-
toxicity of the hexanucleotide expansion (Fig. 4B). 
Transcripts of the offending segments are de-
posited in the nucleus, forming RNA foci that 
sequester nuclear proteins. Some of the expand-
ed RNA escapes to the cytoplasm, where it gen-
erates five potentially toxic repeat dipeptides 
through a noncanonical translation process. 
Recent studies have also shown a defect in trans-
port across the nuclear membrane in cells with 
the C9ORF72 expansions.51,52 A reduction in the 
total levels of the normal C9ORF72 protein may 
also contribute to neurotoxicity.53-55 Transgenic 
mouse models of C9orf72 recapitulate the molecu-
lar features of C9ORF72 ALS in humans56-59 but, 
with one exception,59 do not show a strong mo-
tor phenotype.
Genes That Influence Cytoskeletal Dynamics
Three ALS genes encode proteins that are im-
portant in maintenance of normal cytoskeletal 
dynamics: dynactin 1 (DCTN1),60 PFN1,29 and 
tubulin 4A (TUBA4A) (Fig. 4C).61 TUBA4A dimers 
are components of microtubules, whose integ-
rity is essential for axonal structure; DCTN1 is 
implicated in retrograde axonal transport, where-
as PFN1 participates in the conversion of globu-
lar to filamentous actin and nerve extension. 
Also implicated is the modifier gene EPHA4; 
lower levels of EPHA4 expression correlate with 
longer survival in ALS, perhaps because they 
permit more exuberant axonal extension.
Insights into Sporadic ALS
Despite the absence of a family history in spo-
radic ALS, studies involving twins show that the 
heritability is about 60%.62 Furthermore, muta-
tions usually found in familial ALS can be found 
in sporadic ALS. This can be partly explained by 
the difficulty in ascertaining whether patients 
with late-onset disease have a family history of 
ALS. The situation is confounded by the observa-
tion that some familial ALS gene variants increase 
the risk of phenotypes other than ALS, such as 
frontotemporal dementia.38,39,48 Unless these other 
phenotypes are recognized as relevant, the fam-
ily history may be incorrectly recorded as nega-
tive. In addition, several familial ALS gene vari-
ants are of intermediate penetrance (e.g., the 
C9ORF72 hexanucleotide repeat expansion, ATXN2 
repeat expansions,63 and TBK1 mutations).37-39 
Thus, ALS might not be manifested in a gene 
carrier, in which case, the disease is character-
ized by familial clustering rather than mendelian 
inheritance and may appear to be sporadic.64 
Combinations of such gene variants further in-
crease the risk of ALS and may be another cause 
of apparently sporadic ALS.65
Recent genomewide association studies have 
shown that rare genetic variation is dispropor-
tionately frequent in sporadic ALS.66 The genetic 
architecture of sporadic ALS is markedly differ-
ent from that of complex diseases such as 
schizophrenia in which there are additive effects 
of hundreds of common variants, each with a 
minute effect on risk. However, common vari-
ants still have a part to play in sporadic ALS. For 
example, variants in the genes UNC13A, MOBP, 
and SCFD1 all increase the risk by a small but 
significant degree.66
Heritability studies also show that a substan-
tial fraction of cases of sporadic ALS cannot be 
attributed to genetic or biologic factors; these 
The New England Journal of Medicine 
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cases are ascribed to environmental or undefined 
factors. Attempts to identify occupations or 
common exposures that might increase the risk 
of ALS have been inconclusive. Environmental 
studies are challenging because the number of 
possible exposures is large, and a critical, dis-
ease-related exposure may have happened many 
years before the onset of the disease. A particu-
lar difficulty is that studies of ALS are suscep-
tible to bias because of the poor prognosis. Pa-
tients who live long enough to attend a specialist 
research clinic are different from those identi-
fied in population studies, and this difference 
can cause bias in the results. For instance, smok-
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ing has been shown to shorten survival in a 
population study,67 so a case–control study select-
ing participants from clinics would find smok-
ers underrepresented in the ALS group and 
would thus suggest that smoking either has no 
effect or might be protective. Similarly, ALS spe-
cialists report anecdotally that their patients tend 
to be athletic, slim, and very fit,68 but if these 
factors slow disease progression rather than in-
crease risk, such patients will be overrepresented 
at specialist centers.
Notwithstanding the barriers to identifying 
environmental risk factors, some factors have 
been associated with ALS in multiple studies.69,70 
The exposure with the strongest support is mili-
tary service.71,72 In addition, smoking has been 
implicated as a dose-dependent risk factor for 
ALS.73 Exposure to heavy metals may be impor-
tant; blood lead levels and cerebrospinal fluid 
manganese levels are higher in patients with 
ALS than in controls.70 People with occupations 
involving exposure to electromagnetic fields also 
appear to be at increased risk, but people living 
near power lines are not. Other risk factors with 
varying levels of support include pesticide expo-
sure and neurotoxins such as those produced by 
cyanobacteria. Viruses have been studied as a 
possible explanation for sporadic ALS. Initial 
studies suggesting the role of an activated, endog-
enous retrovirus74 were followed by the identifi-
cation of a possible candidate, human endoge-
nous retrovirus K.75
There is increasing evidence that trauma pre-
cedes some individual cases of ALS.76 A meta-
analysis has suggested that trauma overall, 
trauma occurring more than 5 years previously, 
bone fracture, and head injury are all associated 
with an increased risk.77 In recent years, it has 
been observed that persons engaged in sports 
that entail repetitive concussions or subconcus-
sive head trauma are at increased risk for ALS 
and a concurrent behavioral disorder marked by 
impulsivity and memory loss. Autopsy studies in 
persons with this disorder, called chronic trau-
matic encephalopathy, have revealed fronto-
temporal atrophy associated with distinctive 
deposits of tau protein, as well as TDP-43, the 
characteristic inclusion protein in ALS.78
Ther a peu tics a nd Be yond
No therapy offers a substantial clinical benefit 
for patients with ALS. The drugs riluzole79 and 
edaravone, which have been approved by the 
Food and Drug Administration for the treatment 
of ALS, provide a limited improvement in surviv-
al. Riluzole acts by suppressing excessive motor 
neuron firing, and edaravone by suppressing 
oxidative stress. Numerous other compounds 
that have been investigated have not been shown 
to be effective.80,81 Currently, the mainstay of 
care for patients with ALS is timely intervention 
to manage symptoms, including use of nasogas-
tric feeding, prevention of aspiration (control of 
salivary secretions and use of cough-assist de-
vices), and provision of ventilatory support (usu-
ally with bilevel positive airway pressure). Some 
interventions raise serious ethical issues, such as 
whether to perform tracheostomy for full venti-
lation and, if so, when and how to withdraw 
respiratory support once it has been instituted.
Despite the pipeline of potential treatments 
for ALS, reflecting the expanded list of targets 
Figure 4 (facing page). Three Major Categories  
of Pathophysiological Processes in ALS.
The pathways relating the implicated proteins (red) 
and key cellular structures and molecules (gray) are 
shown. Downstream dysfunctional events are black 
within gray boxes. Panel A shows altered protein ho­
meostasis in ALS. Many ALS genes encode adapter 
proteins that are critical in protein degradation, acting 
at the level of the endoplasmic reticulum (endoplas­
mic reticulum–associated protein degradation [ERAD]) 
and through proteosomal and autophagic pathways. 
RNA­binding proteins may self­assemble to form pri­
on­like aggregates. Panel B shows mechanisms of 
C9ORF72­related disease. The toxicity of expanded 
hexanucleotide repeats in the C9ORF72 gene is pro­
posed to involve depositions of intranuclear RNA, with 
resulting perturbations of gene splicing and sequestra­
tion of RNA­binding proteins; noncanonical translation 
of polydipeptides from the expanded DNA, yielding toxic 
repeat dipeptides; disturbances of nucleocytoplasmic 
transport; and reduced levels of C9ORF72 (haploinsuf­
ficiency). Panel C shows altered neuronal cytoskeletal 
dynamics in ALS. Genes encoding dynactin (DCTN1) 
and tubulin 4A (TUBA4A) are essential in the mainte­
nance of the structure of the motor nerve axon; muta­
tions in these genes disturb both axonal integrity and 
axonal transport. Profilin 1 (PFN1) is essential for the 
assembly of filamentous axons and the formation of 
distal axonal growth cones. PFN1 mutations and in­
creased expression of ephrin A4 (EPHA4) slow the ex­
tension of the distal axon. ADP denotes adenosine di­
phosphate, NF­κB nuclear factor kappa light­chain 
enhancer of activated B cells, and TNF tumor necrosis 
factor.
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identified through genetic studies and increas-
ing numbers of ALS investigators, many of whom 
are in the pharmaceutical sector,80,82 no drugs 
are being investigated in late-phase clinical trials. 
Several innovative approaches to treating ALS 
(and other neurodegenerative diseases) are in 
development. Two examples include the use of 
adeno-associated viruses (AAV) to achieve wide-
spread delivery of diverse cargoes (missing genes, 
therapeutic genes, or gene-silencing elements) to 
the central nervous system and the use of stem 
cells that provide neurotrophic factors to the 
central nervous system.83 Studies in cells, mice, 
and humans support the view that several types 
of reagents (e.g., antisense oligonucleotides and 
AAV-delivered microRNA) inactivate production 
of toxic gene products and thus may be thera-
peutic in ALS mediated by genes such as SOD184-87 
and C9ORF72. Indeed, clinical trials investigating 
the use of antisense oligonucleotides to silence 
SOD1 have begun.
One can anticipate continued progress in 
understanding the biology of ALS. There is no 
doubt that high-throughput genetics, combined 
with improved clinical phenotyping, will further 
refine the genetic landscape of ALS. As thou-
sands of full genome sequences become avail-
able, it will be feasible to explore the possibility 
that complex interactions among multiple gene 
variants explain not only familial ALS but also 
sporadic ALS. The exploration of environmental 
factors in sporadic ALS will expand, with a 
focus on the internal environment represented 
by the microbiome. The ultimate proof of our 
understanding of the biology of ALS will hinge 
on our ability to modify the clinical course of 
the disease.
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